Article
Drug-sensitive FGFR2 mutations in endometrial carcinoma.
Proceedings of the National Academy of Sciences of the United States of America - 24 Jun 2008
Dutt Amit, Salvesen Helga B, Chen Tzu-Hsiu, Ramos Alex H, Onofrio Robert C, Hatton Charlie, Nicoletti Richard, Winckler Wendy, Grewal Rupinder, Hanna Megan, Wyhs Nicolas, Ziaugra Liuda, Richter Daniel J, Trovik Jone, Engelsen Ingeborg B, Stefansson Ingunn M, Fennell Tim, Cibulskis Kristian, Zody Michael C, Akslen Lars A, Gabriel Stacey, Wong Kwok-Kin, Sellers William R, Meyerson Matthew, Greulich Heidi
Abstract excerpt
Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.